Proprietary pharmaceutical data

Access comprehensive pharmaceutical pricing intelligence

Make confident pricing decisions with validated data, traceable to source. Our proprietary datasets combine published prices, reimbursement status and HTA outcomes across 60+ pricing markets, with regulatory intelligence for IRA, MFN and JCA.

Enabled by technology

Spend less time collecting data and more time using it

Market intelligence refreshed monthly, with IRP simulations, scenario modelling, competitor tracking and automated reporting in one platform.

Guided by specialist pricing and market access consulting

Navigate complex pricing and market access challenges with the support of pharmaceutical pricing experts

Our senior consultants have guided successful launches across HTA-led, IRP-driven, and hybrid markets. From early-stage valuation to post-launch, we turn pricing complexity into competitive advantage.

We are the global pharmaceutical pricing experts.
Our proprietary data, purpose-built technology and specialist consulting, delivers your pharmaceutical market advantage.

Global pharmaceuticals trust
Global Pricing Innovations
Navigate

by the challenges you face

Data fragmentation

Disparate data sources hinder a unified view of market access and pricing insights.

Resource constraints

Manual data collection and analysis consume valuable time, delaying strategic decisions.

Market volatility

Rapid shifts in market dynamics make it difficult to maintain competitive pricing.

Budget pressure

Optimising pricing strategies to maximise revenue under increasing cost scrutiny.

Regulatory complexity

Keeping up with IRA, MFN, JCA and HTA policy changes across markets.

Designed

for how you work

Global & Executive
Leadership

Global oversight, IRP governance, launch sequencing and enterprise-wide pricing governance.

Regional & Functional
Leads

Regional alignment, HTA strategies, budget impact, coordination across markets.

Local & Affiliate
Teams

Local data accuracy, contracting & tender intelligence, submission support workflows.

Technical & Integration
Teams

Data infrastructure and automation for pricing and market access systems.
Curated data, enabled by technology, guided by specialist expertise.
Proprietary
data
Analyst-validated intelligence across 60+ pricing markets, refreshed monthly.
Purpose-built technology

A digital interfaces with dashboards, alerts and visual analysis tools.

Specialist consulting

Senior pricing experts guiding decisions across the lifecycle with integrated support from GPI Consulting.

Seamless integration

Plug our data into your own systems with GPI Connect, with no manual entry.

Our services

Find out about GPI's purpose-built technology,
GPI Pulse and GPI Horizon.

Expert team

Senior pharmaceutical pricing specialists with deep market access expertise across global markets, guiding major pharma companies through complex regulatory and competitive landscapes.

Innovative approach

Applying proprietary methodology, curated data and purpose-built technology to complex pharmaceutical pricing and market access challenges, with predictive analytics and expert validation.

Our team collectively brings decades of experience across every discipline.
24 hr response
on data queries
60+
pricing markets
200+ combined years
pricing expertise

Proven results

Trusted by top 10 global pharma companies to accelerate market advantage, optimise launch strategies, and drive measurable ROI.

Why us

GPI delivers

data excellence transformative insights specialist pricing expertise
Purpose-built for pharmaceutical pricing and market access teams
Testimonials

Why our clients love working with us

Our blog

Insights & strategies. Your guide to smarter Pricing and Market Access.

Germany 15.5% rebate

Germany’s 15.5% rebate: what the BStabG means for launch pricing and IRP

Germany’s 15.5% rebate on patented medicines takes effect on 1

gene therapy JCA

The First Gene Therapy JCA: Absence of Evidence Versus Evidence of Absence

Gene therapy JCA submissions face a distinct methodological test, and

Curated by our expert team

Helpful downloads to simplify your challenges

Value-based pricing approaches for oncology products in Germany

Value-based pricing for oncology products in Germany requires a different approach to pre-launch price forecasting. GPI conducted primary research with German payers to identify how value is assessed across 23 attributes grouped into four domains. The results show clinical benefit accounts for 52% of payer value perception, trial design 37%, and burden 11%, reflecting precisely how the G-BA benefit assessment process works under AMNOG in practice.

The research covers both the comparator selection approach and the analogue benchmarking approach for indications where no direct comparators exist, demonstrated through two real-world case studies including one achieving 0.92% accuracy against an actual post-AMNOG reimbursement price. Download below.

Navigating MFN: Turn risk into predictable outcomes

MFN pharmaceutical pricing exposure isn’t discovered — it’s built. The launch and pricing decisions teams make today for entirely rational commercial reasons become the reference points that constrain negotiations twelve to twenty-four months later. The Most Favoured Nation executive order has accelerated this dynamic, but the underlying IRP pressure it creates operates across portfolios regardless of whether a formal MFN clause exists. By the time it’s visible in negotiations, strategic flexibility is already gone.

This guide is written for VP and Director-level global pricing and market access leaders. It covers how exposure builds through daily decisions, why traditional monitoring can’t keep pace, and how GPI Pulse gives teams proactive control — with real application examples from oncology portfolio management across Europe. Download below.

Analogue benchmarking for orphan drug pricing

Analogue benchmarking for orphan drug pricing solves the problem that stops traditional methods in their tracks: generating evidence-based price forecasts when no direct market comparators exist. GPI Horizon predicted pricing for Crysvita (burosumab) within ±5% accuracy across France, Germany, and the UK — with no direct comparators available. The methodology identifies analogues based on shared value drivers drawn from actual HTA documents from G-BA in Germany, HAS in France, and NICE in the UK — not assumed proxies.

The case study covers the full four-domain value framework, the analogue selection methodology, market-specific payer weighting across three European markets, and the pricing accuracy results — delivered during clinical development, while Phase 3 decisions were still shapeable. Download below.

Ready to transform your pricing and market access intelligence?